Biopharmaceutical company Merrimack Pharmaceuticals, Inc. announced the pricing of its initial public offering of 14.3 million common shares at $7.00 per share. All of the shares in the offering are being sold by Merrimack.
The Cambridge, Massachusetts based company common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "MACK" on March 29, 2012.
In an amended regulatory filing with the U.S. Securities and Exchange Commission, the company had lanned to offer 16.67 million shares at a range of $8-$10 per share.
The underwriters also have an option to buy 2.145 million additional shares from Merrimack for a period of 30 days to cover over-allotments.
J.P. Morgan Securities LLC is acting as sole book-running manager for the offering. BofA Merrill Lynch is acting as lead-manager for the offering, and Cowen and Company, LLC and Oppenheimer & Co. Inc. are acting as co-managers for the offering.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.